MedPath

Special Drug Use-Results Survey of Onoact

Not Applicable
Completed
Conditions
tachyarrhythmia, atrial fibrillation/atrial flutter in patients with cardiac dysfunction
Registration Number
JPRN-jRCT1080222572
Lead Sponsor
ONO PHARMACEUTICAL CO., LTD.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
completed
Sex
All
Target Recruitment
800
Inclusion Criteria

Patients with tachyarrhythmia, atrial fibrillation/atrial flutter under cardiac dysfunction for whom Onoact is administered

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety<br>Safety items : Occurrence status of adverse events (including adverse drug reactions)
Secondary Outcome Measures
NameTimeMethod
safety<br>Prognosis untill 180days after Onoact treatment suc as mortality and cardiovascular events
© Copyright 2025. All Rights Reserved by MedPath